6935.TWO Prince Pharmaceutical Co., Ltd.
- Market cap
- TWD 1.27B
- P/E
- 7.7x
- P/B
- 1.47x
- ROE
- 11.5%
- Dividend yield
- 1.83%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6935.TWO undervalued?
Graham number6935.TWO trades 28.9% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Prince Pharmaceutical Co., Ltd. fundamental analysis
No fundamental analysis for Prince Pharmaceutical Co., Ltd. yet.
Prince Pharmaceutical Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Prince Pharmaceutical Co., Ltd.
Prince Pharmaceutical Co., Ltd. manufactures and sells vitamin B1 active pharmaceutical ingredients (APIs) in Taiwan, Japan, Korea, and internationally. The company also offers health food and medicines; vitamin C tablets, vitamin B film-coated tablets, natto and rhodiola extract capsules, probiotic sachets, and plant extract capsules; and API products comprising felbinac, aldioxa, tulobuterol, ufenamate, bisbentiamine, thiamine disulfide, potassium guaiacolsulfonate, potass…
Full company profilePrince Pharmaceutical Co., Ltd. financial statements
Prince Pharmaceutical Co., Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 250M | 296M | 441M | 713M | 753M | 690M | 1.06B |
| Gross Profit | 67.6M | 89.0M | 125M | 206M | 153M | 74.3M | 223M |
| Operating Income | -9.31M | -50.3M | -1.11M | 67.8M | 25.7M | -49.4M | 111M |
| EBITDA | 11.9M | -7.77M | 43.5M | 126M | 88.2M | 20.7M | 176M |
| Net Income | 9.00K | -33.8M | -8.30M | 51.6M | 15.3M | -53.5M | 96.3M |
| EPS | 0.00 | -1.03 | -0.25 | 1.55 | 0.42 | -1.46 | 2.55 |
| Balance Sheet | |||||||
| Total Assets | 1.16B | 1.21B | 1.29B | 1.30B | 1.41B | 1.35B | 1.50B |
| Total Liabilities | 537M | 604M | 688M | 646M | 636M | 626M | 665M |
| Shareholders' Equity | 620M | 611M | 603M | 658M | 774M | 722M | 839M |
| Cash & Short-term Investments | 175M | 57.1M | 72.5M | 72.0M | 123M | 103M | 153M |
| Total Debt | 476M | 525M | 566M | 523M | 490M | 461M | - |
| Cash Flow | |||||||
| Operating Cash Flow | 8.05M | -212K | 42.4M | 91.7M | 62.5M | 46.2M | 90.1M |
| Capital Expenditure | 183M | 187M | 41.3M | 19.8M | 62.2M | 18.0M | 18.8M |
| Free Cash Flow | -175M | -187M | 1.08M | 71.8M | 256K | 28.2M | 71.3M |
| Ratios | |||||||
| ROE | 0.0% | -5.5% | -1.4% | 7.8% | 2.0% | -7.4% | 11.5% |
| ROA | 0.0% | -2.8% | -0.6% | 4.0% | 1.1% | -4.0% | 6.4% |
| Net Profit Margin | 0.0% | -11.4% | -1.9% | 7.2% | 2.0% | -7.8% | 9.1% |
| Debt to Equity | 0.77x | 0.86x | 0.94x | 0.79x | 0.63x | 0.64x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Prince Pharmaceutical Co., Ltd. dividends
- Dividend yield
- 1.83%
- Forward dividend
- 0.50 TWD
- Payout ratio
- -
- Ex-dividend date
- Jul 1, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | TWD 9.15M | 0.25 | - |
| 2023 | TWD 5.43M | 0.15 | 35.5% |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Prince Pharmaceutical Co., Ltd.
Ownership data of Prince Pharmaceutical Co., Ltd. is not available yet.
Prince Pharmaceutical Co., Ltd. company profile
- Company name
- Prince Pharmaceutical Co., Ltd.
- Ticker
- 6935.TWO
- ISIN
- TW0006935000
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 216
- Fiscal year end
- December
- Address
- No.168, Keyun S. Road, Yunlin, Taiwan, 632
- Phone
- 886 5 632 6910
- Website
- prince-pharm.com.tw
About Prince Pharmaceutical Co., Ltd.
Prince Pharmaceutical Co., Ltd. manufactures and sells vitamin B1 active pharmaceutical ingredients (APIs) in Taiwan, Japan, Korea, and internationally. The company also offers health food and medicines; vitamin C tablets, vitamin B film-coated tablets, natto and rhodiola extract capsules, probiotic sachets, and plant extract capsules; and API products comprising felbinac, aldioxa, tulobuterol, ufenamate, bisbentiamine, thiamine disulfide, potassium guaiacolsulfonate, potassium cresolsulfonate, fusultiamine hydrochloride, and fursultiamine. Prince Pharmaceutical Co., Ltd. was founded in 1962 and is headquartered in Yunlin, Taiwan.
Prince Pharmaceutical Co., Ltd. management
2- Da LiGM & Chairman
- Cuiwei ChenAccounting Supervisor